MED27

Across TCGA pan-cancer cohorts, MED27 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MED27 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher MED27 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MED27 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LUSC and BLCA are the cancer types where MED27 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.112	0.762	<.001	30	view →
BLCA	DFS	Median	III,IV	1.000	0.271	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MED27–LUSC (OS)

Open the LUSC breakdown →